Bausch + Lomb (BLCO) news
Recent news
Bausch + Lomb - Expect to raise full-year 2026 adj EBITDA excluding bought IPR&D guidance
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has raised its full-year 2026 guidance for adjusted EBITDA excluding acquired in-process research and development (IPR&D) to a range of $1.025 billion to $1.075 billion, up from its previous guidance of $1.010 billion to $1.060 billion. This increase…
AInvest Wire · 3d agoBausch + Lomb & Bausch Health appio as interim CEO
Bausch Health has appointed appio as the interim chief executive officer (CEO), following a strategic decision to ensure continuity in leadership during a transitional period. The announcement comes amid ongoing efforts to streamline operations and enhance corporate governance within the global…
AInvest Wire · 3d agoBausch + Lomb - Brent Saunders to depart as CEO of Bausch + Lomb
AInvest Wire · 3d agoBausch + Lomb and Bausch Health announce appointment of Thomas J. Appio as interim Bausch + Lomb CEO, expect to raise full-year 2026 guidance
AInvest Wire · 3d agoBausch + Lomb: Barclays initiates coverage with overweight rating and target price C$24
AInvest Wire · Oct 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.